Skip navigation
Oslo Economics logo
About us
News
Our services
Subject areas
Research

Hepatitt C – Nye legemidler gir bedre behandlingsmuligheter

  • Report number:
  • Title: Hepatitt C – Nye legemidler gir bedre behandlingsmuligheter
  • Client: AbbVie
  • Published: August 15
  • Link: PDF
See all publications
Newest articles

EFTA Court annuls decision ordering recovery of unlawful stated aid

Oslo Economics conducted economic analyses of the data ESA used in its decision, on behalf of Arntzen de Besche and Thommessen who represented Eviny AS.

Analysis of the marginal costs of activity growth in the Norwegian specialist health service

Oslo Economics, in collaboration with Sverre Kittelsen (Frisch Centre), Kjartan Sarheim Anthun (SINTEF) and Jon Magnussen (NTNU), has calculated the marginal costs associated with increasing the activity levels in the Norwegian specialist health service. The study is part of the foundation for the Norwegian government’s recently announced healthcare plan and has been conducted on the behalf of the Ministry of Health and Care Services.

New framework agreement with DG Competition: Economic assessment in State aid cases 

Oslo Economics, in collaboration with Schjødt, has entered into another framework agreement with the Directorate-General for Competition (DG Competition) of the European Commission.  
Under this framework agreement, Oslo Economics and Schjødt will provide expert support to DG Competition in state aid cases. This includes assessments of various types of transactions involving the use of State resources, such as equity investments, loans, guarantees, or sales.

Bergen

Markeveien 1, 5012 Bergen
post.bergen@osloeconomics.no

Oslo

Klingenberggata 7A, 0161 Oslo
post@osloeconomics.no
Tel: +47 21 99 28 00
(Hovedkontor)

Berlin

Krausenstraße 9, 10117 Berlin
post@osloeconomics.de

GDPR Aktsomhetsvurderinger Utviklet av Normand Technologies AS